Fermentalg (FALG) Q1 2025 TU earnings summary

Executive summary

• Revenue for Q1 2025 increased by 36% year-over-year to €3.6 million, up from €2.7 million, driven by expansion into new market segments.

• Growth attributed to successful diversification, particularly in pet food, infant formula, and aquaculture sectors with DHA OriginsTM.

• Strategic transformation includes a new commercial organization and enhanced industrial performance via partnership with Huvepharma.

Financial highlights

• Q1 2025 revenue reached €3.6 million, compared to €2.7 million in Q1 2024 and €4 million for full year 2023.

• Revenue trajectory shows significant acceleration, with 2024 revenue expected at €11.5 million.

Outlook and guidance

• Annual revenue target of at least €25 million by 2026, more than six times 2023 revenue.

• 2025 expected to show significant progress over 2023 and 2024, supported by increased sales, partnerships, and innovation.